Irska - angleščina - HPRA (Health Products Regulatory Authority)

milpharm limited - piperacillin tazobactam - pdr for soln inj/inf - 20.25 grams

Irska - angleščina - HPRA (Health Products Regulatory Authority)

milpharm limited - piperacillin tazobactam - pdr for soln inj/inf - 40.5 grams

Velika Britanija - angleščina - myHealthbox

milpharm limited - sildenafil - film-coated tablets - 100mg - urologicals; drugs used in erectile dysfunction - treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. in order for sildenafil to be effective, sexual stimulation is required.

Velika Britanija - angleščina - myHealthbox

milpharm limited - ribavirin - capsule, hard - 200mg - direct acting antivirals, nucleosides and nucleotides (excl.reverse transcriptase inhibitors) - adult patients: ribavirin is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis c except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (alt), who are positive for hepatitis c viral ribonucleic acid hcv-rna children 3 years of age and older and adolescents: ribavirin is intended for use, in a combination regimen with interferon alfa-2b, for the treatment of children and adolescents 3 years of age and older, who have all types of chronic hepatitis c, except genotype 1, not previously treated, without liver decompensation, and who are positive for hcv-rna. when deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. the reversibility of growth inhibition is uncertain. the decision to treat should be made on a case by case basis

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - amisulpride - oral tablet - 200mg

Velika Britanija - angleščina - myHealthbox

milpharm limited - ropinirole - prolonged-release tablet - 8mg - dopamine agonists - treatment of parkinson's disease under the following conditions: initial treatment as monotherapy, in order to delay the introduction of levodopa in combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations)

Velika Britanija - angleščina - myHealthbox

milpharm limited - ropinirole - prolonged-release tablet - 2mg - dopamine agonists - treatment of parkinson's disease under the following conditions: initial treatment as monotherapy, in order to delay the introduction of levodopa in combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations)

Velika Britanija - angleščina - myHealthbox

milpharm limited - ropinirole - prolonged-release tablet - 4mg - dopamine agonists - treatment of parkinson's disease under the following conditions: initial treatment as monotherapy, in order to delay the introduction of levodopa in combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations)

Velika Britanija - angleščina - myHealthbox

milpharm limited - venlafaxine (as hydrochloride) - prolonged-release tablet, hard - 75mg - antidepressants, other antidepressants - treatment of major depressive episodes. for prevention of recurrence of major depressive episodes. treatment of generalised anxiety disorder. treatment of social anxiety disorder. treatment of panic disorder, with or without agoraphobia.

Velika Britanija - angleščina - myHealthbox

milpharm limited - valsartan - capsule, hard - 160mg - angiotensin ii antagonists, plain - hypertension treatment of essential hypertension in adults, and hypertension in children and adolescents 6 to 18 years of age. recent myocardial infarction treatment of clinically stable adult patients with symptomatic heart failure or asymptomatic left ventricular systolic dysfunction after a recent (12 hours – 10 days) myocardial infarction heart failure treatment of symptomatic heart failure in adult patients when angiotensin converting enzyme (ace) inhibitors cannot be used, or as add-on therapy to ace inhibitors when beta blockers cannot be used